Your browser is no longer supported. Please, upgrade your browser.
Paratek Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.19 Insider Own6.40% Shs Outstand45.92M Perf Week-6.74%
Market Cap368.44M Forward P/E- EPS next Y-0.11 Insider Trans-6.61% Shs Float41.56M Perf Month-1.90%
Income-96.50M PEG- EPS next Q-0.32 Inst Own54.30% Short Float10.24% Perf Quarter16.37%
Sales46.90M P/S7.86 EPS this Y44.40% Inst Trans5.26% Short Ratio8.71 Perf Half Y51.66%
Book/sh-2.23 P/B- EPS next Y54.20% ROA-46.20% Target Price- Perf Year72.99%
Cash/sh2.63 P/C2.94 EPS next 5Y- ROE128.40% 52W Range3.81 - 8.75 Perf YTD23.80%
Dividend- P/FCF- EPS past 5Y12.60% ROI-52.50% 52W High-11.43% Beta1.58
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin81.60% 52W Low103.41% ATR0.42
Employees196 Current Ratio6.90 Sales Q/Q77.80% Oper. Margin- RSI (14)52.73 Volatility5.89% 5.74%
OptionableYes Debt/Eq- EPS Q/Q32.70% Profit Margin- Rel Volume0.53 Prev Close7.93
ShortableYes LT Debt/Eq- EarningsFeb 24 AMC Payout- Avg Volume488.67K Price7.75
Recom1.40 SMA203.73% SMA502.11% SMA20027.08% Volume259,136 Change-2.27%
Mar-02-21Initiated Jefferies Buy $15
Nov-09-20Reiterated H.C. Wainwright Buy $19 → $22
Jan-08-20Initiated WBB Securities Speculative Buy $6
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
Mar-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-24-17Initiated Guggenheim Buy $44
Jul-18-17Reiterated H.C. Wainwright Buy $36 → $43
May-19-17Initiated Raymond James Strong Buy
Apr-11-17Reiterated H.C. Wainwright Buy $33 → $36
Apr-04-17Reiterated Wedbush Outperform $30 → $34
Apr-04-17Initiated Wedbush Outperform $30
Oct-27-16Resumed Leerink Partners Outperform $23
Jun-17-16Reiterated H.C. Wainwright Buy $31 → $34
May-13-16Initiated Robert W. Baird Outperform $30
Mar-30-16Resumed Cantor Fitzgerald Buy $27
Feb-29-16Initiated H.C. Wainwright Buy $32
Jul-22-15Initiated Gabelli & Co Buy $34
May-15-15Initiated Leerink Partners Outperform
Apr-12-21 01:59PM  
Apr-01-21 04:01PM  
Mar-01-21 04:01PM  
Feb-25-21 12:01AM  
Feb-24-21 04:01PM  
Feb-18-21 04:01PM  
Feb-17-21 04:01PM  
Feb-10-21 12:06AM  
Feb-08-21 08:00AM  
Feb-01-21 04:05PM  
Jan-06-21 08:00AM  
Jan-04-21 05:00PM  
Dec-25-20 04:07AM  
Dec-10-20 09:40PM  
Dec-01-20 04:05PM  
Nov-12-20 04:01PM  
Nov-05-20 06:35PM  
Nov-02-20 04:05PM  
Oct-29-20 12:35PM  
Oct-27-20 08:00AM  
Oct-26-20 02:52PM  
Oct-21-20 08:00AM  
Sep-09-20 04:01PM  
Sep-01-20 04:05PM  
Aug-25-20 10:17AM  
Aug-10-20 08:45AM  
Aug-05-20 04:01PM  
Aug-03-20 04:05PM  
Jul-28-20 04:01PM  
Jul-05-20 03:05PM  
Jun-12-20 04:46PM  
May-29-20 08:30AM  
May-28-20 08:00AM  
May-11-20 04:05PM  
Apr-30-20 08:00AM  
Apr-28-20 12:14PM  
Apr-14-20 12:26PM  
Apr-02-20 08:00AM  
Apr-01-20 08:00AM  
Mar-14-20 10:55AM  
Mar-10-20 05:12PM  
Mar-02-20 04:05PM  
Feb-27-20 11:50AM  
Feb-26-20 08:00AM  
Feb-25-20 05:35PM  
Feb-24-20 07:00AM  
Feb-17-20 01:36PM  
Feb-13-20 04:01PM  
Jan-14-20 03:12PM  
Dec-20-19 08:38AM  
Dec-19-19 09:33PM  
Dec-18-19 05:12PM  
Dec-13-19 03:06PM  
Dec-10-19 12:22PM  
Dec-06-19 08:00AM  
Dec-02-19 04:05PM  
Nov-30-19 11:02AM  
Nov-28-19 06:59PM  
Nov-13-19 12:14PM  
Nov-12-19 05:15PM  
Nov-05-19 10:31AM  
Nov-04-19 04:05PM  
Nov-01-19 04:05PM  
Oct-31-19 04:05PM  
Oct-29-19 10:32AM  
Oct-18-19 07:07AM  
Oct-17-19 04:05PM  
Oct-01-19 04:30PM  
Sep-25-19 08:00AM  
Sep-24-19 08:50AM  
Sep-23-19 01:16PM  
Sep-10-19 01:58PM  
Sep-09-19 08:00AM  
Sep-04-19 08:00AM  
Sep-03-19 04:05PM  
Aug-30-19 01:31PM  
Aug-26-19 04:05PM  
Aug-13-19 02:07AM  
Aug-06-19 05:45PM  
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIGHAM MICHAELExec. Chairman of the BoardDec 14Sale6.7126,063174,883546,517Dec 15 07:47 PM
Brenner Randall B.Chief Development & RegulatoryDec 14Sale6.718,76058,780128,782Dec 15 07:50 PM
Haskel William M.CLO, General Counsel & Sec.Dec 14Sale6.716,84245,910203,267Dec 15 07:52 PM
Woodrow AdamPresident & Chief CommercialDec 14Sale6.7112,85586,257271,273Dec 15 07:54 PM
Loh EvanCEODec 14Sale6.7126,415177,245600,559Dec 15 07:56 PM
Loh EvanCEODec 11Sale6.9518,585129,166626,974Dec 15 07:56 PM
Woodrow AdamPresident & Chief CommercialDec 11Sale6.959,04562,863284,128Dec 15 07:54 PM
Haskel William M.CLO, General Counsel & Sec.Dec 11Sale6.954,81433,457210,109Dec 15 07:52 PM
Brenner Randall B.Chief Development & RegulatoryDec 11Sale6.956,16442,840137,542Dec 15 07:50 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 11Sale6.9518,337127,442572,580Dec 15 07:47 PM
Loh EvanCEONov 13Sale5.9320,928124,103645,559Nov 16 06:36 PM
Brenner Randall B.Chief Development & RegulatoryNov 13Sale5.938,35749,557143,706Nov 16 06:33 PM
BIGHAM MICHAELExec. Chairman of the BoardNov 13Sale5.9326,250155,662590,917Nov 16 06:30 PM
Haskel William M.CLO, General Counsel & Sec.Nov 13Sale5.936,89240,870214,923Nov 16 06:28 PM
Woodrow AdamPresident & Chief CommercialNov 13Sale5.9315,00088,950293,173Nov 16 06:23 PM
Loh EvanCEOOct 29Option Exercise4.3039,479169,760591,487Nov 02 04:50 PM
Haskel William M.Sr. VP, Sec. & General CounselMay 12Sale4.754,66622,164198,690May 14 06:42 PM
Brenner Randall B.Chief Development & RegulatoryMay 12Sale4.756,19829,440130,813May 14 06:38 PM
Woodrow AdamPresident & Chief CommercialMay 12Sale4.754,79822,790270,673May 14 06:30 PM
Loh EvanCEOMay 12Sale4.759,59545,576552,008May 14 06:27 PM
BIGHAM MICHAELExec. Chairman of the BoardMay 12Sale4.6812,25057,330542,167May 14 06:23 PM